US court rules Zytiga patent invalid

27 October 2018

The US District Court, District of New Jersey on Friday issued a ruling invalidating all asserted claims of US Patent No 8,822,438 for Zytiga (abiraterone acetate), healthcare giant Johnson & Johnson’s (NYSE: NJ) blockbuster prostate cancer drug, so opening the door to generic competition.

The Court held that the patent claims would be infringed if the patent were valid. The patent infringement case was filed against several companies who have submitted Abbreviated New Drug Applications for 250mg and/or 500mg tablets, including Teva Pharmaceutical Industries (NYSE: TEVA) and Mylan (Nasdaq: MYL).

Zytiga had US sales of $1.4 billion in the first nine months of 2018, up 72% on the like 2017 period. J&J’s shares dipped 1.08% to $136.97 by close of trading.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK